Potential of D‐cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials
Tóm tắt
Hyperactivation of glutamatergic N‐methyl‐D‐aspartate (NMDA) receptors has been implicated in the excitotoxicity and pathophysiology of Parkinson's disease (PD). NMDA receptor blockers have been used clinically to treat dementia, but their efficacy is controversial. Modulation of NMDA receptors might improve neuroinflammation and cognitive deficits in PD. D‐cycloserine (DCS), a partial agonist binding to the glycine binding site of NMDA receptors, has been demonstrated to improve cognitive function in primates and rodents. Our previous study showed that DCS can reduce motor, emotional, and cognitive dysfunctions, as well as neuroinflammation and neurodegeneration in a PD animal model and may therefore have potential for the treatment of neuroinflammation and cognitive dysfunction in patients with PD. In addition, increased expression of cyclooxygenase type‐2 (COX‐2) has been observed in dopaminergic neurons and activated microglia in the brain of both PD patients and PD animal models. COX‐2 inhibitors can suppress activation of microglia and protect dopaminergic neurons from degeneration. Thus, a combination of DCS and COX‐2 inhibitors might prove useful in suppressing neuroinflammation and cognitive deficits in PD.
Tài liệu tham khảo
Javitt D.C., 2002, Glycine modulators in schizophrenia, Curr Opin Investig Drugs, 3, 1067
10.1016/0006-8993(90)90745-W
10.1016/0304-3940(89)90379-0
10.1111/j.1460-9568.2007.05488.x
10.1016/0197-4580(94)90114-7
10.1097/00001756-199702100-00024
10.1001/archpsyc.63.3.298
10.1176/ajp.152.8.1213
10.1016/S0010-440X(61)80007-2
10.1016/0091-3057(89)90571-6
10.1016/S0028-3908(01)00085-5
10.1016/j.bbr.2003.10.028
10.1016/0014-2999(92)90709-D
10.1016/S0006-8993(00)02036-9
10.1111/j.1530-0277.1997.tb04501.x
10.1007/s002130000547
10.1016/j.bbr.2007.09.013
10.1016/j.brainres.2005.02.057
10.1016/S0006-8993(98)01043-9
10.1096/fj.06-7856com
10.1016/j.bbr.2009.11.006
10.1073/pnas.0837397100
10.1016/j.brainres.2006.05.016
Choi S.H., 2003, Thrombin‐induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo, J Neurosci, 23, 5877, 10.1523/JNEUROSCI.23-13-05877.2003
10.1111/j.1471-4159.2006.04327.x
10.1111/j.1749-6632.2003.tb07482.x
10.1096/fj.05-5106com
10.1016/S0140-6736(84)92807-1
10.1037/0894-4105.9.1.126
10.1212/WNL.56.6.730
10.1001/archneur.60.3.387
10.1212/WNL.41.3.365
10.1093/brain/123.4.733
10.1016/S1474-4422(03)00351-X
10.2741/1171
10.1016/j.parkreldis.2004.01.005
Abramsky O., 1978, Autoimmune response to dopamine‐receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia, Perspect Biol Med, 22, 104
10.1358/dot.1999.35.6.544933
10.1007/978-3-7091-6360-3_7
10.1016/0091-3057(89)90007-5
10.1523/JNEUROSCI.0116-07.2007
10.1007/PL00007757
10.1006/exnr.1999.7293
10.1111/j.1471-4159.2006.04330.x
10.1038/89490
10.1016/0304-3940(94)90508-8
10.1016/0304-3940(94)90746-3
10.1016/S0304-3940(98)00427-3
Nagatsu T., 2000, Changes in cytokines and neurotrophins in Parkinson's disease, J Neural Transm Suppl, 60, 277
T.Nagatsu M.Mogi H.Ichinose A.Togari.Cytokines in Parkinson's disease.J Neural Transm Suppl.2000;143–151
10.2174/1381612053381620
10.1007/s10571-006-9061-9
10.1007/BF01291792
10.1016/0304-3940(96)12706-3
10.1111/j.1750-3639.2001.tb00401.x
10.1038/emm.2006.40
10.1176/ajp.150.9.1408
10.1176/ajp.152.9.1291
10.1016/S1074-7427(03)00008-X
10.1016/j.jneumeth.2005.04.005
10.1016/S0361-9230(01)00501-9
10.1016/S0361-9230(02)00754-2
10.1097/00008877-200205000-00001
10.1016/j.bbr.2011.01.028
10.1016/j.ejphar.2008.07.022
10.1016/S0162-3109(98)00022-8
10.1016/j.nbd.2005.01.023
10.1016/S0014-4886(02)00050-X
10.1016/j.cnr.2006.09.006
10.1007/s00401-003-0766-2
10.1037/a0017401
10.1016/j.pbb.2009.12.020
10.2165/00002512-200320050-00006
10.1152/jn.1994.72.2.507
10.1016/0306-4522(95)00535-8
10.1002/mds.10156
10.1523/JNEUROSCI.14-11-06317.1994
Kornhuber J., 1994, Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties, J Neural Transm Suppl, 43, 91
10.1001/archneur.1991.00530210109030
10.1016/0024-3205(94)00387-4
10.1212/WNL.67.7_suppl_2.S30
10.1001/jama.1969.03160070046011
10.1212/WNL.50.5.1211
10.1002/mds.20968
10.1667/RR0588.1
10.1038/72945
10.1016/j.nlm.2004.03.005
10.1016/j.neuint.2008.06.006
10.1101/lm.46102
10.1097/00008877-200311000-00006
Matsuoka N., 1996, D‐cycloserine, a partial agonist at the glycine site coupled to N‐methyl‐D‐aspartate receptors, improves visual recognition memory in rhesus monkeys, J Pharmacol Exp Ther, 278, 891
10.1016/S0163-1047(89)90313-0
10.1016/0091-3057(90)90140-D
10.1016/0091-3057(91)90039-5
10.1038/319774a0
10.1038/ncpneuro0322
Reynolds I.J., 1988, Multiple sites for the regulation of the N‐methyl‐D‐aspartate receptor, Mol Pharmacol, 33, 581
10.1111/j.1471-4159.1989.tb07344.x
10.1016/0301-0082(90)90040-N
10.1073/pnas.85.17.6547
10.1016/j.schres.2004.03.013
10.1017/S1461145702003061
K.Laake A.R.Oeksengaard.D‐cycloserine for Alzheimer's disease.Coch Data Sys Rev.2002 CD003153
10.1038/sj.npp.1300517
Mandell G.L., 1996, The pharmacological basis of therapeutics, 1164
Ruiz R.C., 1964, D‐Cycloserine in the treatment of pulmonary tuberculosis resistant to the standard drugs: a study of 116 cases, Diseases of the Chest, 45, 181, 10.1378/chest.45.2.181
10.1016/S0893-133X(96)00196-0
10.1016/S0006-3223(96)00311-3
Hanngren H., 1961, Antibiotics, Chemotherapy, 12, 45
Chuang T., 2011, D‐cycloserine facilitates the effects of exposure therapy on phobias, Formos J Med, 15, 1
10.1016/S0028-3908(97)00130-5
10.1007/s00213-007-0816-x
10.1002/syn.20241
10.1523/JNEUROSCI.12-12-04793.1992
10.1007/3-211-30714-1_69
10.1002/ana.20338
10.2174/1568006043481284
10.1016/j.jneuroim.2008.08.003
10.1007/s00441-004-0944-0
M.Sawada K.Imamura T.Nagatsu.Role of cytokines in inflammatory process in Parkinson's disease.J Neural Transm Suppl.2006;373–381
Wang T., 2005, MPP+‐induced COX‐2 activation and subsequent dopaminergic neurodegeneration, FASEB J, 19, 1134, 10.1096/fj.04-2457fje
10.1523/JNEUROSCI.22-05-01763.2002
10.1523/JNEUROSCI.15-07-05263.1995
10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5
10.1093/brain/123.11.2321
10.1007/s00702-004-0123-1
10.1016/j.expneurol.2007.02.008
10.1016/j.neulet.2008.03.031
10.1016/j.neulet.2009.05.033
10.3923/pjbs.2007.3853.3858
10.1016/j.ejphar.2006.12.032
10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U
10.1186/1742-2094-1-6
10.1186/1742-2094-3-6
10.1007/BF03033170
10.1016/S0163-7258(98)00042-4
10.1016/0006-8993(93)91239-O
10.1016/0014-2999(94)90687-4
10.1016/j.nlm.2005.01.001
10.1001/archpsyc.61.11.1136
10.1016/j.jpsychires.2006.05.006